Biden wants to take drug price fight to Medicaid; a battle for the soul of Illumina

Taking stock of the drug industry, from the lab to the medicine chest

May 24, 2023 Check out STAT+

Sponsored By

By Ed Silverman Pharmalot Columnist, Senior Writer

APStock STAT+ | Congress took on high drug prices in Medicare. Now Biden wants to take it to Medicaid The Biden administration wants to help states control Medicaid prescription drug costs by making prices more transparent. By John Wilkerson STAT+ | Annexon's trial of an eye disease drug missed by a mile. The company saw a bull's eye While the eye disease drug failed to achieve the main goal of a mid-stage clinical trial, the company had a more optimistic interpretation. By Adam Feuerstein STAT+ | Boston Scientific cancels $230 million deal to buy Korean device company Boston Scientific is scrapping its $230 million plan to buy a majority stake in M.I. Tech. Instead, it will purchase a minority stake. By Lizzy Lawrence World Economic Forum/Faruk Pinjo STAT+ | Battle for the soul of Illumina is also a referendum on its CEO Francis deSouza has served as CEO since 2016 and shown a leadership style in stark contrast to that of his predecessor, Jay Flatley. By Matthew Herper We'll soon have tools to protect infants against RSV. Can we put them to good use? There are sizable hurdles standing in the way of the implementation of both a new vaccine and a monoclonal antibody. By Helen Branswell

More around STAT

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

---

Enjoying Pharmalot? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

STAT, 1 Exchange Place, Boston, MA ©2023, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser